Floyd E. Fox

2.5k total citations
58 papers, 2.0k citations indexed

About

Floyd E. Fox is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Floyd E. Fox has authored 58 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 25 papers in Molecular Biology and 16 papers in Immunology. Recurrent topics in Floyd E. Fox's work include Angiogenesis and VEGF in Cancer (11 papers), Cutaneous lymphoproliferative disorders research (9 papers) and Lymphoma Diagnosis and Treatment (9 papers). Floyd E. Fox is often cited by papers focused on Angiogenesis and VEGF in Cancer (11 papers), Cutaneous lymphoproliferative disorders research (9 papers) and Lymphoma Diagnosis and Treatment (9 papers). Floyd E. Fox collaborates with scholars based in United States, Netherlands and Canada. Floyd E. Fox's co-authors include Alain H. Rook, Hagop Youssoufian, Zhutian Niu, Eric K. Rowinsky, E. Gabriela Chiorean, Roger B. Cohen, Cindy L. O’Bryant, Laura Q.M. Chow, Sami Diab and D. Ross Camidge and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Floyd E. Fox

56 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Floyd E. Fox United States	23	807	711	492	416	336	58	2.0k
Raquel Villuendas Spain	29	1.1k 1.3×	812 1.1×	361 0.7×	161 0.4×	333 1.0×	47	2.4k
Brigitte Lankat–Buttgereit Germany	22	304 0.4×	1.1k 1.5×	273 0.6×	116 0.3×	166 0.5×	46	1.9k
András Schaffer United States	23	422 0.5×	696 1.0×	1.1k 2.3×	146 0.4×	253 0.8×	44	2.2k
Vijaya Chaturvedi United States	24	477 0.6×	1.2k 1.7×	415 0.8×	113 0.3×	225 0.7×	39	2.0k
Shenghui Duan United States	19	704 0.9×	1.3k 1.8×	1.2k 2.5×	201 0.5×	785 2.3×	30	3.4k
Martin Holcmann Austria	17	508 0.6×	476 0.7×	738 1.5×	131 0.3×	220 0.7×	27	1.6k
Edgar Dippel Germany	24	516 0.6×	476 0.7×	722 1.5×	112 0.3×	693 2.1×	112	2.1k
Jesús Pérez‐Losada Spain	27	1.1k 1.4×	1.6k 2.3×	254 0.5×	302 0.7×	248 0.7×	71	2.7k
Gunter Rappl Germany	24	900 1.1×	899 1.3×	736 1.5×	125 0.3×	136 0.4×	42	2.1k
Erika Darrah United States	23	335 0.4×	634 0.9×	871 1.8×	279 0.7×	70 0.2×	62	2.5k

Countries citing papers authored by Floyd E. Fox

Since Specialization

Citations

This map shows the geographic impact of Floyd E. Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Floyd E. Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Floyd E. Fox more than expected).

Fields of papers citing papers by Floyd E. Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Floyd E. Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Floyd E. Fox. The network helps show where Floyd E. Fox may publish in the future.

Co-authorship network of co-authors of Floyd E. Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Floyd E. Fox. A scholar is included among the top collaborators of Floyd E. Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Floyd E. Fox. Floyd E. Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zamarin, Dmitriy, Omid Hamid, Asha Nayak-Kapoor, et al.. (2020). Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research. 26(17). 4531–4541. 52 indexed citations

Petrylak, Daniel P., Kim N., Nicholas J. Vogelzang, et al.. (2012). Randomized phase II study of docetaxel with or without ramucirumab (IMC-1121B) or icrucumab (IMC-18F1) in patients with urothelial transitional cell carcinoma (TCC) following progression on first-line platinum-based therapy.. Journal of Clinical Oncology. 30(15_suppl). TPS4675–TPS4675. 3 indexed citations

Rowinsky, Eric K., Jonathan D. Schwartz, Naseem J. Zojwalla, et al.. (2011). Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers. Current Drug Targets. 12(14). 2016–2033. 23 indexed citations

Malempati, Suman, Brenda J. Weigel, Charlotte H. Ahern, et al.. (2009). A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study. Journal of Clinical Oncology. 27(15_suppl). 10013–10013. 10 indexed citations

Robinson, Douglas, David Mauro, Christine Chung, et al.. (2008). Utility of cetuximab-cross reactive IgE as a predictive biomarker for cetuximab associated severe infusion reactions. Clinical Cancer Research. 14. 1 indexed citations

Chiorean, Elena G., Christopher Sweeney, S. Savage, et al.. (2007). Phase I dose-escalation study of the anti-VEGFR-2 recombinant human IgG1 MAb IMC-1121B administered every other week (q2w) or every 3 weeks (q3w) in patients (pts) with advanced cancers. Molecular Cancer Therapeutics. 6. 12 indexed citations

LoRusso, Patricia, Michael A. Gordon, Evan Y. Yu, et al.. (2007). A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis. Molecular Cancer Therapeutics. 6. 9 indexed citations

Rothenberg, Mace L., et al.. (2007). Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors. Molecular Cancer Therapeutics. 6. 17 indexed citations

Cohen, Robert, D. Ross Camidge, Sami Diab, et al.. (2006). 647 POSTER A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer. European Journal of Cancer Supplements. 4(12). 195–195. 3 indexed citations

10.

Kuendgen, A., Barbara Hildebrandt, Floyd E. Fox, et al.. (2005). P-112 Results of a phase II trial with valproic acid (VPA) alone or in combination with all-trans-retinoic acid (ATRA) in 71 patients with myelodysplastic syndromes or SAML/MDS. Leukemia Research. 29. S66–S66. 1 indexed citations

11.

Fox, Floyd E., et al.. (2002). Effects of 2 Different Anti–Tumor Necrosis Factor–α Agents in a Primate Model of Subcutaneous Abscess Formation. The Journal of Infectious Diseases. 185(2). 204–213. 11 indexed citations

12.

Showe, Louise C., et al.. (1999). Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4.. PubMed. 163(7). 4073–9. 42 indexed citations

13.

Showe, Louise C., et al.. (1999). Depressed IL-12-Mediated Signal Transduction in T Cells from Patients with Sezary Syndrome Is Associated with the Absence of IL-12 Receptor β2 mRNA and Highly Reduced Levels of STAT4. The Journal of Immunology. 163(7). 4073–4079. 44 indexed citations

14.

Fox, Floyd E., Zhutian Niu, Alfonso J. Tobia, & Alain H. Rook. (1998). Photoactivated Hypericin is an Anti-Proliferative Agent that Induces a High Rate of Apoptotic Death of Normal, Transformed, and Malignant T Lymphocytes: Implications for the Treatment of Cutaneous Lymphoproliferative and Inflammatory Disorders. Journal of Investigative Dermatology. 111(2). 327–332. 59 indexed citations

15.

Fox, Floyd E., Marek Kubin, Maureen Cassin, et al.. (1997). Calcitonin Gene-Related Peptide Inhibits Proliferation and Antigen Presentation by Human Peripheral Blood Mononuclear Cells: Effects on B7, Interleukin 10, and Interleukin12. Journal of Investigative Dermatology. 108(1). 43–48. 95 indexed citations

16.

Rook, Alain H., Floyd E. Fox, Zhutian Niu, et al.. (1996). The Potential Therapeutic Role of Interleukin‐12 in Cutaneous T‐Cell Lymphomaa. Annals of the New York Academy of Sciences. 795(1). 310–318. 29 indexed citations

17.

Gottlieb, Scott, Jonathan Wolfe, Floyd E. Fox, et al.. (1996). Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institution. Journal of the American Academy of Dermatology. 35(6). 946–957. 157 indexed citations

18.

Zhou, Heng, Eric J. Bernhard, Floyd E. Fox, & Paul C. Billings. (1993). Induction of metalloproteinase activity in human T-lymphocytes. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1177(2). 174–178. 44 indexed citations

19.

Kunicka, Jolanta E., et al.. (1989). Human Suppressor Factors Constitutively Produced by T-T Cell Hybridomas: Functional and Biochemical Characterization. Hybridoma. 8(2). 127–151. 7 indexed citations

20.

Platsoucas, Chris D., Floyd E. Fox, Emilia L. Oleszak, et al.. (1989). Regulation of natural killer cytotoxicity by recombinant alpha interferons. Augmentation by IFN-alpha 7, an interferon similar to IFN-alpha J.. PubMed. 9(4). 849–58. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact